Latest Breaking News On - Carlos buesa - Page 6 : comparemela.com

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial

Carlos buesaMichael ropackiDouglasv fallerData monitoring committeeOryzon genomicsIndependent data monitoring committeeChief medical officerGlobal chief medical officerKabuki syndromeChief executive officer

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesColumbia universityComunidad autonoma de catalunaCarlos buesaDevelopment agreementUs national cancer instituteUniversity of copenhagenSpanish ministry of scienceEuropean conference on mental healthExchange euro dollarSeaver autism centerFox chase cancer centerChief executive officerCancer epigenetics instituteNeuroendocrine cancers

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022

17.02.2023 - Strong clinical progress in both oncology and CNS Cash, cash equivalents and marketable securities totaled $22.7 million as of December 31, 2022 MADRID, Spain and BOSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) - Oryzon Genomics, S.A. (ISIN .

New yorkUnited statesColumbia universityComunidad autonoma de catalunaPatricia coboAshleyr robinsonCarlos buesaDaniel foleySaikat nandiDevelopment agreementUs national cancer instituteUniversity of copenhagenLifesci advisorsSpanish ministry of scienceEuropean conference on mental healthExchange euro dollar

ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients with First-line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022

ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients with First-line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesComunidad autonoma de catalunaCarlos buesaOlga salameroDouglas fallerAmerican society of hematologyDevelopment agreementUs national cancer instituteFox chase cancer centerWall streetAmerican societyAnnual conferenceEffective treatmentFirst line acute myeloidFinal resultsHebron hospital

Spain s Oryzon shares soar after US Cancer Institute agrees to test new drug | WKZO | Everything Kalamazoo

MADRID (Reuters) - Shares of Spanish biopharma company Oryzon Genomics soared on Tuesday after the U.S. National Cancer Institute agreed to test a new.

Comunidad autonoma de catalunaEmma pinedoChristina thykjaerCarlos buesaEd osmondUs national cancer instituteOryzon genomicsCancer instituteInti landauro